MCTA Charming Medical Ltd

Overview and Growth

Fiscal 2026 results for Charming Medical Ltd combined $4.81M of revenue with net loss of $22.65K and an operating cash outflow of $1.22M. The $4.81M revenue base provides substantial context for the company’s earnings, cash generation, and capital requirements. The top line contracted 22.7% from $6.22M in fiscal 2025; this top-line contraction left the company with a smaller revenue base. On a per-share basis, diluted EPS was $0.00, which connects the reported earnings outcome with the company’s diluted share count. Against diluted EPS of $0.08 in fiscal 2025, the current result was 100.0% lower. Revenue equaled 0.49x of total assets, indicating how much reported top-line activity the company produced relative to its period-end asset base.

Profitability

Gross profit was $4.77M, representing the portion of revenue remaining after the reported cost of revenue and before operating expenses. Gross profit represented 99.3% of revenue, showing how much of the top line remained after direct costs. The reported operating result was an operating loss of $29.24K, reflecting costs that exceeded gross profit. The operating loss equaled 0.6% of revenue, showing the scale of the operating deficit relative to sales. After all below-operating-line items, the company recorded a net loss of $22.65K for the fiscal year. Net margin was -0.5%, reflecting a loss equal to 0.5% of reported revenue. The earnings statement records $133.47K of pretax income, the profit base against which the reported tax provision can be assessed. Pretax income represented 2.8% of revenue, placing earnings before tax in the context of the company’s operating scale. The company recognized $156.11K of income tax for the period, completing the transition from pretax income to net income. The income-tax provision equaled 117.0% of pretax income, showing the tax burden absorbed by the year’s earnings. The net loss equaled 0.4% of period-end equity, showing the deficit relative to book capital.

Liquidity and Capital Structure

The company held $9.87M of assets against $4.69M of liabilities and $5.18M of equity, revealing how the asset base was financed. Current assets were $8.17M against $4.33M of current liabilities, framing the resources and obligations classified within the near-term balance-sheet horizon. The current ratio was 1.89x, with current assets exceeding current liabilities and providing a short-term liquidity cushion. Reported cash and equivalents were $4.70M, separating immediately recognizable cash resources from the rest of the current-asset base. Measured only with cash and equivalents, coverage of current liabilities was 108.5%, excluding receivables and other current assets. Borrowings totaled $371.60K, adding a fixed financing obligation alongside the company’s equity capital. The debt-to-equity relationship was 0.07x, showing how much debt the company carried for each unit of book equity. Debt represented 3.8% of total assets, placing borrowing in the context of the company’s full resource base. Liabilities represented 47.5% of total assets, quantifying the liability-funded share of the company’s resource base. Cash and equivalents equaled 47.6% of total assets, showing the liquid cash component within the company’s broader resource base. Total assets were 84.3% higher than fiscal 2025 assets of $5.36M, measuring the company’s own balance-sheet change.

Cash Flow and Earnings Quality

The company reported an operating cash outflow of $1.22M, rather than cash generation from operations. Capital spending of $339.56K added to the period’s operating cash use, reinforcing the overall cash deficit after investment for the year. Negative free cash flow was $1.56M, leaving a cash deficit after capital spending and reducing financial flexibility. Relative to revenue, the post-investment cash deficit represented 32.4%. The free-cash-flow deficit equaled 15.8% of total assets, placing the cash shortfall against the company’s resource base.

Based on the annual report for the fiscal year ending Mar 31, 2026. Analysis generated Oct 21, 2026.